4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0000950170-25-096268
Chief Scientific Officer sold 8,500 shares at $14.00 ($118,962)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-07-15 | Sale 10b5-1 | −8,500 | $14.00 | $118,962 | 435,142 | D: show line 1 in the form |
| Open-market sales · 8,500 sh · avg $14.00 · $118,962 | |||||||
Loading xslF345X05/ownership.xml…